diaDexus, Inc. – ‘8-K’ for 9/30/03

On:  Wednesday, 10/1/03, at 9:33pm ET   ·   As of:  10/2/03   ·   For:  9/30/03   ·   Accession #:  1169232-3-5906   ·   File #:  0-26483

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3      9K 
 2: EX-99.1     Press Release                                          3     15K 

8-K   —   Current Report
Document Table of Contents

8-K
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

----------------------

FORM 8-K

CURRENT REPORT

 Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2003

VAXGEN, INC.
(Exact name of Registrant as Specified in its Charter)

  DELAWARE                  0-26483               94-3236309
(State or other jurisdiction of    (Commission          (I.R.S. Employer        
incorporation or organization)      File Number)         Identification Number) 

 1000 MARINA BLVD., SUITE 200 BRISBANE, CALIFORNIA 94005
 (Address of Principal Administrative Offices)

 Registrants Telephone Number, Including Area Code: (650) 624-1000

8-K
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
Item 5.  Other Events and Regulation FD Disclosure.                             

On September 30, 2003, VaxGen, Inc. issued a press release entitled,
"VaxGen Awarded $80.3 Million NIAID Contract for Advanced Development of Anthrax
Vaccine Candidate". This press release is attached as Exhibit 99.1 to this      
report and is incorporated herein by reference.                                 

Item 7.  Financial Statements, Pro Forma Financial Information and Exhibits.    

(c) Exhibits.                                                       

Exhibit No.        Description                                                  
-----------        -----------                                                  

99.1               Press release dated September 30, 2003, entitled, "VaxGen    
                   Awarded $80.3 Million NIAID Contract for Advanced Development
of Anthrax Vaccine Candidate".            

8-K
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
 SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the        
registrant has duly caused this report to be signed on its behalf by the        
undersigned hereunto duly authorized.                                           

                          VaxGen, Inc.
                          (Registrant)

Dated: September 30, 2003                      By: /s/ Carter A. Lee            
                                   ---------------------
                                Carter Lee
                                           Senior Vice President
                                              Finance & Administration

Dates Referenced Herein   and   Documents Incorporated by Reference

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed as of:		10/2/03
Filed on:		10/1/03
For Period End:		9/30/03		1		3			10-Q,  NT 10-Q
									List all Filings